FDC Limited

FDC Limited announced that it received an order from the Assistant Commissioner of Income Tax, Circle – 1(3)(1), Mumbai, on November 3, 2026, giving effect to an order passed by the Commissioner of Income Tax Appeals - 56 for assessment year 2016-17, resulting in an aggregate refund of Rs 14.20 crore.

FDC Ltd share price inched up 2.36% to Rs 353.95. The Company's net profit plunged by 62.97% to Rs 49.06 crore, while revenue from operations reduced 14.31% to Rs 572.14 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.44 lakh crore, rising 4.06%. It has marginally improved by 3.17% over last one week and eased lower by 0.26% in last one month while the market capitalization of FDC Ltd has improved by 4.23% and 12.84% in the same period respectively. Profit before tax (PBT) of FDC Ltd stood at Rs 65.41 crore in Q3 FY26, surging by 71.72% year-on-year, and tanking 62.56% quarter-on-quarter. EBITDA came in at Rs 46 crore, rallying 251.67% YoY and crashing by 51.38% sequentially. Total expenses marginally dropped 2.96% to Rs 523.83 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 139.94 crore, slightly declining by 3.16% YoY, while employee benefits expense was at Rs 134.28 crore, registering a marginal contraction of 0.65% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 2.98% to Rs 2170.93 crore, while net profit saw a marginal increase of 5.48% to Rs 281.42 crore, compared to previous TTM. EBITDA surged by 23865% to Rs 232.58 crore, and PBT saw a minor gain of 4.87% to Rs 374.6 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 200.45 crore in FY26, as against Rs 317.57 crore in FY25. FDC Ltd crashed 18.08% in last one year, significantly underperforming the benchmark BSE Sensex which has reduced by 13.19% during the same period.

FDC Ltd share price inched up 2.36% to Rs 353.95. The Company's net profit witnessed a sharp fall of 62.97% to Rs 49.06 crore, while revenue from operations declined 14.31% to Rs 572.14 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.54 lakh crore, rising 3.36%. It has marginally improved by 2.52% over last one week and dipped slightly by 0.63% in last one month while the market capitalization of FDC Ltd has improved by 2.97% and 14.57% in the same period respectively. Profit before tax (PBT) of FDC Ltd stood at Rs 65.41 crore in Q3 FY26, expanding by 71.72% year-on-year, and plunging by 62.56% quarter-on-quarter. EBITDA came in at Rs 46 crore, jumping 251.67% YoY and nosediving by 51.38% sequentially. Total expenses slightly declined by 2.96% to Rs 523.83 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 139.94 crore, slightly declining by 3.16% YoY, while employee benefits expense was at Rs 134.28 crore, dipping slightly 0.65% YoY. For the TTM ended FY26, revenue from operations grew marginally by 2.98% to Rs 2170.93 crore, while net profit grew slightly 5.48% to Rs 281.42 crore, compared to previous TTM. EBITDA soared by 23865% to Rs 232.58 crore, and PBT saw a minor gain of 4.87% to Rs 374.6 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 200.45 crore in FY26, as against Rs 317.57 crore in FY25. FDC Ltd tumbled by 19.96% in last one year, underperforming the benchmark BSE Sensex which has slipped by 13.18% during the same period.

FDC Limited will hold a board meeting on Tuesday, October 27, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, and to consider a proposal for the buyback of fully paid-up equity shares through a tender offer route. The company closed its trading window for directors and designated persons from October 1, 2026, until 48 hours after the declaration of the financial results.

FDC Limited informed the BSE Limited and National Stock Exchange of India Ltd. that MUFG Intime India Private Limited, formerly Link Intime India Pvt. Ltd., issued a certificate regarding the details of securities dematerialized/rematerialized for the quarter ended September 30, 2026, in compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

FDC Limited will hold its 86th Annual General Meeting on September 24, 2026, and has declared a book closure from September 17, 2026, to September 23, 2026, with a cut-off date of September 16, 2026, to determine eligible voters, according to a regulatory filing.

FDC Limited (NSE: FDC, BSE: 531599) announced its unaudited financial results for the first quarter ended June 30, 2026, reporting consolidated revenue from operations of Rs. 668 crore, a 3.0% year-over-year increase compared to Rs. 648 crore in the same quarter of the previous year, driven primarily by the performance of International Formulations, particularly the US business, while Domestic Formulations and APIs remained relatively muted. The company also received U.S. FDA approval for Cefixime for Oral Suspension USP 100mg/5mL and 200mg/5mL during the quarter.

FDC Ltd share price remained flat to Rs 403.0. The Company's net profit soared by 28.13% to Rs 132.49 crore, while revenue from operations gained 14.18% to Rs 667.69 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, rising 5.74%. It has marginally improved by 0.41% over last one week and advanced by 11.45% in last one month while the market capitalization of FDC Ltd has eased by 2.73% and 7.34% in the same period respectively. Profit before tax (PBT) of FDC Ltd stood at Rs 174.7 crore in Q2 FY26, easing 9.34% year-on-year, and jumping 24.47% quarter-on-quarter. EBITDA came in at Rs 95 crore, slipping 9.08% YoY and surging by 68.80% sequentially. Total expenses grew marginally by 9.55% to Rs 539.82 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 144.5 crore, marginally falling by 2.97% YoY, while employee benefits expense was at Rs 135.16 crore, surging 23.66% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 8.50% to Rs 2108.12 crore, while net profit dropped 12.55% to Rs 266.79 crore, compared to previous TTM. EBITDA surged by 24972% to Rs 234.14 crore, and PBT saw a marginal contraction of 9.84% to Rs 357.22 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 317.57 crore in FY26, as against Rs 220.77 crore in FY25. FDC Ltd nosedived by 16.33% in last one year, underperforming the benchmark BSE Sensex which has eased by 3.20% during the same period.

FDC will hold a meeting of the Board of Directors of the Company on 5 August 2026.

Net profit of FDC rose 167.39% to Rs 103.40 crore in the quarter ended March 2026 as against Rs 38.67 crore during the previous quarter ended March 2025. Sales rose 18.89% to Rs 584.79 crore in the quarter ended March 2026 as against Rs 491.89 crore during the previous quarter ended March 2025. For the full year,net profit rose 5.48% to Rs 281.42 crore in the year ended March 2026 as against Rs 266.79 crore during the previous year ended March 2025. Sales rose 2.98% to Rs 2170.93 crore in the year ended March 2026 as against Rs 2108.12 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales584.79491.89 19 2170.932108.12 3 OPM %18.1910.97 -15.9415.41 - PBDT154.7068.87 125 454.63410.95 11 PBT140.3553.31 163 395.39357.22 11 NP103.4038.67 167 281.42266.79 5 Powered by Capital Market - Live